Meeting
2024 ASCO Genitourinary Cancers Symposium
AIM high: Epigenetic modulation and immune stimulation in bladder cancer.
Authors
Elizabeth Leone Koehne
University of Washington, Seattle, WA
Elizabeth Leone Koehne , Sonali Arora , Kevin Wang , Yan Wang , Martine Roudier , Khursheed Ali , Andrew Caleb Hsieh , James Dai , Michael C. Haffner , Hung-Ming Lam , Jonathan L. Wright
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 648)
DOI
10.1200/JCO.2024.42.4_suppl.648
Abstract #
648
Poster Bd #
J12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
ARID1A deficiency in triple-negative breast cancer induces adaptive immune resistance and sensitivity to immune checkpoint inhibitors.
First Author: Margaret Chen
Poster
2020 Genitourinary Cancers Symposium
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).
First Author: Ziad Bakouny
Poster
2024 ASCO Annual Meeting
Development of a novel risk stratification model for immune-related adverse events for patients with advanced melanoma and non-small cell lung cancer treated with immune checkpoint inhibitors.
First Author: Yizhuo Kelly Gao
Poster
2024 ASCO Genitourinary Cancers Symposium
AI-based morphologic model for prediction of individual patient response to immune checkpoint inhibitors for bladder cancer.
First Author: Monica Nair